Policy & Regulation
![](/-/media/editorial/buildings/government_us-and-international/beis.jpg?rev=a4a8b42c0d4949f4a0bfbcdc8f229c40&w=784&hash=CFBBEA1BED13A0CB5B162CAF4AED764B)
New National Security Checks Could Hinder Investment, Warns UK Biotech Sector
Life science SMEs and their investors need to comply with new UK government checks on their dealmaking.
![](/-/media/editorial/scrip/2021/05/sc0520_brexit_p8je5t_1200.jpg?rev=af01698daca44d82881f9fa0242cbb47)
Novo Nordisk On The Pluses And Minuses Of The UK Post-Brexit R&D Environment
Post-Brexit Britain offers a fertile R&D ecosystem, but it needs to improve uptake in novel medicines there and strike a lasting deal with the EU over batch testing, Novo Nordisk’s UK general manager Pinder Sahota tells Scrip.
Policy
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Policy
FTC’s PBM Investigation Could Yield Litigation Over Insulin Contracting
The US Federal Trade Commission’s focus on potential anti-competitive behavior by pharmacy benefit managers picks up steam as Chair Lina Khan approaches the end of her term.
IGBA’s Almeida On Patent Quality, Single Data Package Globally For Off-Patent Drugs
IGBA's secretary general, in an interview with Scrip, bolsters the case for enabling single global development of off-patent medicines and the acceptance of foreign comparators in bioequivalence studies as complex and niche therapeutics increasingly dot pharma’s pipeline. The global off-patent industry association, she maintained, is also “paying attention” to patent quality in various regions.
As India Scales CAR-T Efforts, Can It Innovate Commercial Models?
As India seeks to build on early gains in CAR-T cell therapy, experts call for ecosystem reform and also the need to demonstrate value to payer models of large economies to potentially back international reimbursements.
SK pharmteco Focusing On BAU Amid BIO 'Buzz', BIOSECURE
SK pharmteco CEO Joerg Ahlgrimm talks to Scrip about the "excitement" at BIO, potential CDMO shifts amid the US BIOSECURE Act, and the Korean CDMO's focus on business as usual as it seeks to diversify and grow.
China Biotech Podcast: BIOSECURE Act Updates ASCO Highlights
US-based Citeline writer Sarah Karlin-Smith joins Brian Yang and Dexter Yan in China to discuss the US BIOSECURE Act and the recent BIO meeting in San Diego, while Dexter Yan discusses China-related ASCO highlights, in this mixed Chinese- and English-language episode.
BIO Notebook: Califf On RWE, Industry Execs On Growing Therapeutic Areas, And More
Insights from Day Four of the BIO International Convention include FDA commissioner Califf on the state of real-world evidence and how it impacts IRA negotiations, Roche's interest in cardiovascular/metabolic assets, Merck's plans in immunology, and industry's rising interest in neuropsychiatry.
Regulation
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Regulation
IGBA’s Almeida On Patent Quality, Single Data Package Globally For Off-Patent Drugs
IGBA's secretary general, in an interview with Scrip, bolsters the case for enabling single global development of off-patent medicines and the acceptance of foreign comparators in bioequivalence studies as complex and niche therapeutics increasingly dot pharma’s pipeline. The global off-patent industry association, she maintained, is also “paying attention” to patent quality in various regions.
India Inc Calls For Regulatory Easing; Looks To Biosimilar Launches Including Keytruda
Speaking of an impending launch of new biosimilars, including pembrolizumab, panelists at a recent event in India asked for regulatory easing from a waiver of Phase III trials for biosimilars to a single body for pre-clinical and trial approvals. The chicken and egg question of VC funding also came up.
AstraZeneca Moves To Join Invyvid In COVID-19 Prevention
The UK giant’s COVID-19 prophylactic sipavibart could soon reach Europe and competition is sparse.
VC-Led Biotech Model Systemically Difficult To Adopt In Korea
A research fellow at South Korea's Science and Technology Policy Institute talked at a recent seminar about the key funding, management and other challenges faced by the domestic biotech sector to sustain growth, and how these contrast with the situation in the US.
Parexel Execs On Obesity Drug Hurdles, Parexel GPT, India RWD Opportunity
Parexel’s chief strategy officer Kushal Gohil, Clinical EVP Stephen Pyke and India head Sanjay Vyas share thoughts on possible hurdles to, and the cascading impact of obesity treatments, GenAI progress and the opportunities and challenges of real-world data in India, in the second of this two-part interview with Scrip.
Conditional Global-First Nod For SanBio's Cell Therapy for TBI
SanBio’s lead cell therapy asset has been on a bumpy journey to its global-first approval and while a nod has now come in Japan in a high-need indication, a commercial launch is conditional on additional data to establish product equivalence and manufacturing consistency.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.